| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The frequency of peripheral regulatory B cells (Bregs) was significantly higher in gastric cancer (GC) patients than in healthy controls. The frequency of Bregs in GC tissue was significantly higher than in peripheral blood and healthy gastric tissue. We also confirmed that the same phenomenon could be observed in esophageal and colorectal cancer. With regard to the function of Bregs obtained from GC patients, carboxyfluorescein succinimidyl ester labeling revealed that Bregs could suppress the proliferation of autologous CD4+ T cells. Moreover, Bregs inhibited the production of interferon-gamma by CD4+ T cells. Double staining immunohistochemistry of interleukin-10 and CD19 revealed 5-year overall survival rates of patients with BregHigh (13.3%) was significantly lower than that of patients with BregLow (65.4%, P < 0.0001). Multivariate analysis indicated that the frequency of Bregs was an independent prognostic indicator in GC patients.
|
